Read More

Johnson & Johnson’s Carvykti Stands Ahead Of Bristol Myers’ Rival Blood Cancer Therapy With FDA Approval For Wider Population

FDA approves Johnson & Johnson's Carvykti, a BCMA-targeted therapy for relapsed or refractory multiple myeloma patients, offering hope with increased manufacturing capacity and extended collaboration efforts.

JNJ

Read More

Bristol Myers’ $14B Bet On Schizophrenia – Drug Cuts Symptoms Without Common Side Effect Of Weight Gain Associated With Other Antipsychotics

Interim data from Bristol Myers Squibb's Phase 3 EMERGENT program on KarXT's safety, tolerability, and metabolic outcomes in adults with schizophrenia. Find out how KarXT demonstrated favorable impacts on weight and long-term metabolic profile over 52 weeks of treatment.

BMY